IMPROVEMENT OF EFFICIENCY OF TREATMENT OF ABDOMINAL CANCEROMATOSIS BY INTRAPERITONEAL POLYCHEMOTHERAPY ON MODEL OF DISSEMINATED OVARIAN CANCER
Vol. 64 No. 3 (2018), ORIGINAL ARTICLES. B. EXPERIMENTAL RESEARCH
Vol. 64 No. 3 (2018)

IMPROVEMENT OF EFFICIENCY OF TREATMENT OF ABDOMINAL CANCEROMATOSIS BY INTRAPERITONEAL POLYCHEMOTHERAPY ON MODEL OF DISSEMINATED OVARIAN CANCER

ORIGINAL ARTICLES. B. EXPERIMENTAL RESEARCH
https://doi.org/10.37469/0507-3758-2018-64-3-440-444
Published 01.03.2018
Viktor Bespalov
N.N. Petrov National Medical Research Center of Oncology, ITMO University
Irina Vasileva
N.N. Petrov National Medical Research Center of Oncology
Grigoriy Tochilnikov
N.N. Petrov National Medical Research Center of Oncology
Aleksandr Semenov
N.N. Petrov National Medical Research Center of Oncology
Aleksandr Stukov
N.N. Petrov National Medical Research Center of Oncology
Valeriy Aleksandrov
N.N. Petrov National Medical Research Center of Oncology
Ye. Vyshinskaya
N.N. Petrov National Medical Research Center of Oncology
##article.numberofdownloads## 25
##article.numberofviews## 74
PDF (Русский)

Keywords

OVARIAN CANCER
ABDOMINAL CANCEROMATOSIS
INTRAPERITONEAL CHEMOTHERAPY

How to Cite

Bespalov, V., Vasileva, I., Tochilnikov, G., Semenov, A., Stukov, A., Aleksandrov, V., & Vyshinskaya, Y. (2018). IMPROVEMENT OF EFFICIENCY OF TREATMENT OF ABDOMINAL CANCEROMATOSIS BY INTRAPERITONEAL POLYCHEMOTHERAPY ON MODEL OF DISSEMINATED OVARIAN CANCER. Voprosy Onkologii, 64(3), 440–444. https://doi.org/10.37469/0507-3758-2018-64-3-440-444
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Intraperitoneal chemotherapy can potentially significantly improve the results of treatment of patients with abdominal carcinomatosis in ovarian cancer (OC). The aim of the study was to compare the antitumor activity of the combined action of cytostatics: dioxadet and melphalan, dioxadet and mitomycin C with their intraperiponeal administration, with the effects of these drugs in mono mode. In the model of transplanted ovarian tumor in 74 female rats, a single dose was administered: dioxadet, melphalan, or mitomycin C in doses of 1.5; 2; 1.5 mg/kg body weight, respectively, or a combination of these drugs in half doses. Antitumor effects of the treatment were assessed by the median survival time (MST) of rats in various groups. Dioxadet, mitomycin C and melphalan with an intraperitoneal administration statistically significantly increased the MST by 67, 28 and 103 %, respectively. The combination of dioxadet and mitomycin C did not show a significant additive antitumor effect. The combination of dioxadet and melphalan showed a potentiating effect, significantly increased the VST by 186 %, and can be recommended for clinical trials in patients with disseminated OC.
https://doi.org/10.37469/0507-3758-2018-64-3-440-444
##article.numberofdownloads## 25
##article.numberofviews## 74
PDF (Русский)

References

Беспалов В.Г, Беляева О.А., Панченко А.В. и др. Противоопухолевое действие диоксадэта в сравнении с цисплатином на модели асцитной опухоли яичника у крыс // Вопр. Онкол. - 2011. - Т. 57. - № 6. - С. 771-774.

Беспалов В.Г., Вышинская Е.А., Васильева И.Н. и др. Сравнительное исследование противоопухолевой эффективности цитостатиков при внутрибрюшинном и внутривенном введении на модели диссеминированного рака яичника у крыс // Бюлл. эксп. биол. мед. - 2016. - Т. 162. - № 9. - С. 370-373.

Вышинская Е.А., Беспалов В.Г., Васильева И.Н. и др. Преимущества интраперитонеальной химиотерапии в лечении канцероматоза брюшной полости при раке яичника//Журнал акушерства и женских болезней. - 2014. - Т. 63. - № 2. - С. 28-34.

Вышинская Е.А., Беспалов В.Г., Васильева И.Н. и др. Новые схемы интраперитонеальной полихимиотерапии для лечения канцероматоза брюшной полости при раке яичников//Журнал акушерства и женских болезней. - 2014. - Т. 63. - № 5. - С. 46-53.

Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, ГВ. Петровой. - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. - 250 с.

Auer K., Bachmayr-Heyda A., Aust S. et al. Peritoneal tumor spread in serous ovarian cancer - epithelial mesenchymal status and outcome // Oncotarget. - 2015. - Vol. 6. - № 19. - P 17261-17275.

Chamber B.A., Lynch Th.J., Longo D.L. Harrisons's Manual of oncology. - Mc Graw Hill Medical: New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, Milan, New Delhi, San Juan, Seoul, Singapore, Sydney, Toronto, 2008. - 625 ps.

GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [Электронный ресурс]. URL: http://globocan.iarc.fr. (дата обращения 11.01.2018 г.)

Orlando D., Schärer O.D. DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses//Chem. Biochem. - 2005. - Vol. 6. - Р. 27-32.

Paz M.M., Zhang X., Lu J., Holmgren A. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase// Chemical Research in Toxicology. - 2012. - Vol. 25. - № 7. - P 1502-1511.

Samuels B.L., Bitran J.D. High-dose intravenous melphalan: a review // J. Clin. Oncol. - 1995. - Vol. 13. - № 7. - P 1786-1799.

Trimble E.L., Christian M.C. National Cancer Institute - United States strategy regarding intraperitoneal chemotherapy for ovarian cancer//Int. J. Gynecol. Cancer. - 2008. - Vol. 18. - Suppl. 1. - P. 26-28. - DOI: 10.1111/j.1525-1438.2007.01100.x

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2018

Most read articles by the same author(s)